SCHEDULE 13G/A: Biotechnology Value Fund Group Discloses 7.0% Passive Stake in Elevation Oncology, Inc. via Warrants

A group of investment entities led by Biotechnology Value Fund and Mark N. Lampert has disclosed a combined beneficial ownership of 7.0% in Elevation Oncology, Inc., primarily through exercisable warrants.

Summary

• As of March 31, 2025, a group of reporting persons, including Biotechnology Value Fund, L.P. (BVF), Biotechnology Value Fund II, L.P. (BVF2), Biotechnology Value Trading Fund OS LP (Trading Fund OS), and their related general partners and investment managers, collectively beneficially owned 4,440,000 shares of Elevation Oncology, Inc. common stock.
• This beneficial ownership represents approximately 7.0% of the outstanding shares, calculated based on 59,215,795 shares outstanding as of February 28, 2025, plus the 4,440,000 shares underlying the warrants.
• The shares are held through Purchase Warrants, which are immediately exercisable at an exercise price of $2.25 per whole share and expire on June 13, 2028.
• A 'Warrants Blocker' provision limits exercise if it would result in beneficial ownership exceeding 9.99% of outstanding shares or combined voting power, but this blocker did not limit the exercise of any warrants held by the reporting persons as of March 31, 2025.
• Individual beneficial ownership percentages include BVF at approximately 3.9% (2,374,712 shares), BVF2 at approximately 3.0% (1,826,364 shares), and Trading Fund OS at approximately 0.4% (210,388 shares).
• BVF GP Holdings LLC is deemed to beneficially own approximately 6.6% (4,201,076 shares), while BVF Partners L.P., BVF Inc., and Mark N. Lampert are each deemed to beneficially own approximately 7.0% (4,440,000 shares).

Sentiment

Score: 5

Explanation: The document is a factual disclosure of beneficial ownership and does not contain subjective language or performance metrics that would indicate a positive or negative sentiment. It is neutral in tone and content.

Positives

• The Warrants Blocker, which limits beneficial ownership to 9.99%, did not restrict the exercise of any warrants held by the reporting persons as of March 31, 2025, indicating full exercisability of their current holdings.

Risks

• The Warrants Blocker provision could limit future exercise of warrants if the beneficial ownership threshold of 9.99% is approached or exceeded, potentially restricting the reporting persons' ability to increase their stake or influence.

Future Outlook

This Schedule 13G filing is a disclosure of beneficial ownership and does not contain forward-looking statements or guidance from Elevation Oncology, Inc. or the reporting persons regarding the company's future performance.

Industry Context

This filing indicates a significant passive investment by a specialized biotechnology fund group in Elevation Oncology, Inc., a company operating in the biotechnology sector. Such disclosures are common for institutional investors accumulating or adjusting their stakes in publicly traded companies, particularly in growth-oriented sectors like biotechnology where strategic investments can signal confidence or a long-term view.

Related Party Transactions

• The filing details the interconnected ownership and control structure among the various Biotechnology Value Fund entities (BVF, BVF2, Trading Fund OS, BVF GP, BVF2 GP, Partners OS, BVF GPH, Partners, BVF Inc.) and Mark N. Lampert, who collectively report beneficial ownership and shared voting/dispositive power over the shares.

Stakeholder Impact

• Shareholders: The disclosure of a significant 7.0% stake by a prominent biotechnology investment group may be viewed positively by existing shareholders, potentially signaling institutional confidence in Elevation Oncology, Inc. It also highlights a concentration of ownership.
• Company Management: Awareness of a large institutional holder can influence strategic decisions, although the filing states the holding is not for the purpose of changing or influencing control, other than activities solely in connection with a nomination under Rule 14a-11.

Key Dates

Keywords

Elevation Oncology, Biotechnology Value Fund, Schedule 13G, Beneficial Ownership, Warrants, Common Stock, Passive Investment, SEC Filing, Biotechnology